Evolution of drug resistance in bacteria

Advances in Experimental Medicine and Biology

Volumn 915, Issue , 2016, Pages 49-67

  Waclaw, B ^a  

^a UNIVERSITY OF EDINBURGH   (United Kingdom)

Author keywords

Antibiotic resistance; Biological evolution; Modelling infection

Indexed keywords

ANTIBIOTIC AGENT; BETA LACTAM ANTIBIOTIC; CIPROFLOXACIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT; TOBRAMYCIN; ANTIINFECTIVE AGENT;

ANTIBIOTIC RESISTANCE; AVASCULAR NECROSIS; BACTERIAL GROWTH; BACTERIAL INFECTION; BACTERIUM; COMPUTER MODEL; CYSTIC FIBROSIS; DRUG CONCENTRATION; DRUG DISTRIBUTION; EVOLUTION; GENE MUTATION; HUMAN; LUNG INFECTION; MATHEMATICAL ANALYSIS; MICROBIAL POPULATION DYNAMICS; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRIORITY JOURNAL; PSEUDOMONAS INFECTION; SOFT TISSUE INFECTION; WOUND INFECTION; ANIMAL; BACTERIAL INFECTIONS; BIOLOGICAL MODEL; DRUG EFFECTS; GENETICS; GENOTYPE; HOST PATHOGEN INTERACTION; MICROBIOLOGY; MOLECULAR EVOLUTION; PATHOGENICITY; PHENOTYPE; POPULATION DYNAMICS; TIME FACTOR;

ANIMALS; ANTI-BACTERIAL AGENTS; BACTERIA; BACTERIAL INFECTIONS; DRUG RESISTANCE, BACTERIAL; EVOLUTION, MOLECULAR; GENOTYPE; HOST-PATHOGEN INTERACTIONS; HUMANS; MODELS, BIOLOGICAL; PHENOTYPE; POPULATION DYNAMICS; TIME FACTORS;

EID: 84979007776     PISSN: 00652598     EISSN: 22148019     Source Type: Book Series    
DOI: 10.1007/978-3-319-32189-9_5     Document Type: Chapter

References (67)

1. Adam U. Herms S, Werner U, Strubelt H, Makowiec F, Hopt UT, Drewelow B (2001) The penetration of ciprofloxacin into human pancreatic and peripancreatic necroses in acute necrotizing pancreatitis. Infection 29(6):326–331. doi:10.1007/s15010-001-1158-y. http://link. springer.com/article/10.1007/s15010-001-1158-y
2. Andrews JM (2001) Determination of minimum inhibitory concentrations. J Antimicrob Chemother 48(suppl 1):5–16. doi:10.1093/jac/48.suppl_1.5. http://jac.oxfordjournals.org/content/48/suppl_1/5
3. Antibiotic resistance threats in the United States (2013). http://www.cdc.gov/drugresistance/pdf/arthreats-2013-508.pdf
4. Austin D, Kristinsson K, Anderson R (1999) The relationship between the volume of antimicrobial consumption in human communities and the frequency of resistance. Proc Natl Acad Sci 96 (3):1152
5. Barclay ML, Begg EJ, Chambers ST, Thornley PE, Pattemore PK, Grimwood K (1996) Adaptive resistance to tobramycin in Pseudomonas aeruginosa lung infection in cystic fibrosis. J Antimicrob Chemother 37(6):1155–1164. http://jac.oxfordjournals.org/content/37/6/1155.short
6. Benveniste R, Davies J (1973) Mechanisms of antibiotic resistance in bacteria. Annu Rev Biochem 42(1):471–506. doi: 10.1146/annurev.bi.42.070173.002351. http://www.annualreviews.org/doi/abs/10.1146/annurev.bi.42.070173.002351
7. Bergan T (1981) Pharmacokinetics of tissue penetration of antibiotics. Rev Infect Dis 3(1):45–66. http://cid.oxfordjournals.org/content/3/1/45.short
8. Bollenbach T, Quan S, Chait R, Kishony R (2009) Nonoptimal microbial response to antibiotics underlies suppressive drug interactions. Cell 139(4):707–718. doi:10.1016/j.cell.2009.10.025. http://linkinghub.elsevier.com/retrieve/pii/S0092867409013154
9. Bonhoeffer S, Lipsitch M, Levin B (1997) Evaluating treatment protocols to prevent antibiotic resistance. Proc National Acad Sci 94(22):12106–12111
10. Bos J, Zhang Q, Vyawahare S, Rogers E, Rosenberg SM, Austin RH (2015) Emergence of antibiotic resistance from multinucleated bacterial filaments. Proc National Acad Sci 112 (1):178–183. doi:10.1073/pnas.1420702111. http://www.pnas.org/content/112/1/178
11. Bowler PG, Duerden BI, Armstrong DG (2001) Wound microbiology and associated approaches to wound management. Clin Microbiol Rev 14(2):244–269. doi:10.1128/CMR.14.2.244-269.2001. http://cmr.asm.org/content/14/2/244
12. Brandis G, Wrande M, Liljas L, Hughes D (2012) Fitness-compensatory mutations in rifampicin-resistant RNA polymerase: fitness compensation of RifR. Mol Microbiol 85 (1):142–151. doi:10.1111/j.1365-2958.2012.08099.x. http://doi.wiley.com/10.1111/j.1365- 2958.2012.08099.x
13. Casley-Smith JR, Sims MA, Harris JL (1976) Capillary lengths and areas, and intercapillary distances in tissue near the human knee. Experientia 32(1):64–66. doi:10.1007/BF01932625. http://link.springer.com/article/10.1007/BF01932625
14. Chait R, Craney A, Kishony R (2007) Antibiotic interactions that select against resistance. Nature 446(7136):668–671. doi:10.1038/nature05685. http://www.nature.com/doifinder/10.1038/nature05685
15. Crump B, Wise R, Dent J (1983) Pharmacokinetics and tissue penetration of ciprofloxacin. Antimicrob Agents Chemother 24(5):784–786. doi:10.1128/AAC.24.5.784. http://aac.asm.org/content/24/5/784
16. Davies J, Davies D (2010) Origins and evolution of antibiotic resistance. Microbiol Mol Biol Rev 74(3):417–433. doi:10.1128/MMBR.00016-10. http://mmbr.asm.org/cgi/doi/10.1128/MMBR. 00016-10
17. Donlan RM, Costerton JW (2002) Biofilms: survival mechanisms of clinically relevant microorganisms. Clin Microbiol Rev 15(2):167–193. doi:10.1128/CMR.15.2.167-193.2002. http://cmr.asm.org/content/15/2/167
18. Eron LJ, Harvey L, Hixon DL, Poretz DM (1985) Ciprofloxacin therapy of infections caused by Pseudomonas aeruginosa and other resistant bacteria. Antimicrob Agents Chemother 28 (2):308–310. doi:10.1128/AAC.28.2.308. http://aac.asm.org/content/28/2/308
19. Finch R et al (2012) Antimicrobial chemotherapy, 6 edn. Oxford University Press
20. Foo J, Choi N, Leder K, Mumenthaler S, Pao W, Michor F, Mallick P, Heise N (2015) The Impact of microenvironmental heterogeneity on the evolution of drug resistance in cancer cells. Cancer Inf 19. doi:10.4137/CIN.S19338. http://www.la-press.com/the-impact-of-microenvironmentalheterogeneity- on-the-evolution-of-dru-article-a4945
21. Fu F, Nowak MA, Bonhoeffer S (2014) Spatial heterogeneity in drug concentrations can facilitate the emergence of resistance to cancer therapy. arXiv preprint arXiv:1411.6684. http://arxiv.org/abs/1411.6684
22. Gibson RL, Burns JL, Ramsey BW (2003) Pathophysiology and management of pulmonary infections in cystic fibrosis. Am J Respir Crit Care Med 168(8):918–951. doi:10.1164/rccm. 200304-505SO. http://www.atsjournals.org/doi/abs/10.1164/rccm.200304-505SO
23. Gillespie SH, Basu S, Dickens AL, O’Sullivan DM, McHugh TD (2005) Effect of subinhibitory concentrations of ciprofloxacin on Mycobacterium fortuitum mutation rates. J Antimicrob Chemother 56(2):344–348. doi:10.1093/jac/dki191. http://jac.oxfordjournals.org/content/56/2/344
24. Greulich P, Waclaw B, Allen RJ (2012) Mutational pathway determines whether drug gradients accelerate evolution of drug-resistant cells. Phys Rev Lett 109(8). doi:10.1103/PhysRevLett. 109.088101. http://link.aps.org/doi/10.1103/PhysRevLett.109.088101
25. Greulich P, Scott M, Evans MR, Allen RJ (2015) Growth-dependent bacterial susceptibility to ribosome-targeting antibiotics. Mol Syst Biol 11(3):796–796. doi:10.15252/msb.20145949. http://msb.embopress.org/cgi/doi/10.15252/msb.20145949
26. Gullberg E, Cao S, Berg OG, Ilbäck C, Sandegren L, Hughes D, Andersson DI (2011) Selection of resistant bacteria at very low antibiotic concentrations. PLoS Pathog 7(7), e1002,158. doi:10. 1371/journal.ppat.1002158. http://dx.plos.org/10.1371/journal.ppat.1002158
27. Heisig P, Tschorny R (1994) Characterization of fluoroquinolone-resistant mutants of escherichia coli selected in vitro. Antimicrob Agents Chemother 38(6):1284–1291. http://aac.asm.org/content/38/6/1284.short
28. Hermsen R, Deris JB, Hwa T (2012) On the rapidity of antibiotic resistance evolution facilitated by a concentration gradient. Proc Natl Acad Sci 109(27):10775–10780
29. Honeybourne D (1994) Antibiotic penetration into lung tissues. Thorax 49(2):104–106. http://thorax.bmj.com/content/49/2/104.full.pdf
30. Kepler T, Perelson A (1998) Drug concentration heterogeneity facilitates the evolution of drug resistance. Proc National Acad Sci 95(20):11,514
31. Kim S, Lieberman TD, Kishony R (2014) Alternating antibiotic treatments constrain evolutionary paths to multidrug resistance. Proc National Acad Sci 201409800. doi:10.1073/pnas.1409800111. http://www.pnas.org/content/early/2014/09/16/1409800111
32. Koch G, Yepes A, Förstner KU, Wermser C, Stengel ST, Modamio J, Ohlsen K, Foster KR, Lopez D (2014) Evolution of resistance to a last-resort antibiotic in staphylococcus aureus via bacterial competition. Cell 158(5):1060–1071. doi:10.1016/j.cell.2014.06.046. http://www. sciencedirect.com/science/article/pii/S0092867414008733
33. König C, Simmen HP, Blaser J (1998) Bacterial concentrations in pus and infected peritoneal fluid–implications for bactericidal activity of antibiotics. J Antimicrob Chemother 42(2):227–232. doi:10.1093/jac/42.2.227. http://jac.oxfordjournals.org/content/42/2/227
34. Lambert G, Estévez-Salmeron L, Oh S, Liao D, Emerson B, Tlsty T, Austin R (2011) An analogy between the evolution of drug resistance in bacterial communities and malignant tissues. Nat Rev Cancer 11(5):375–382
35. Lee H, Popodi E, Tang H, Foster PL (2012) Rate and molecular spectrum of spontaneous mutations in the bacterium Escherichia coli as determined by whole-genome sequencing. Proc National Acad Sci U.S.A. 109(41):E2774–E2783. doi:10.1073/pnas.1210309109. http://www. ncbi.nlm.nih.gov/pmc/articles/PMC3478608/
36. Levin BR, Rozen DE (2006) Non-inherited antibiotic resistance. Nature Reviews Microbiology 4 (7):556–562. http://www.nature.com/articles/nrmicro1445
37. Lipsitch M, Levin B (1997) The population dynamics of antimicrobial chemotherapy. Antimicrob Agents Chemother 41(2):363
38. Lipsky BA, Hoey C (2009) Topical antimicrobial therapy for treating chronic wounds. Clin Infect Dis 49(10):1541–1549. doi:10.1086/644732. http://cid.oxfordjournals.org/content/49/10/1541
39. Maisnier-Patin S, Berg OG, Liljas L, Andersson DI (2002) Compensatory adaptation to the deleterious effect of antibiotic resistance in Salmonella typhimurium. Mol Microbiol 46 (2):355–366. doi:10.1046/j.1365-2958.2002.03173.x. http://onlinelibrary.wiley.com/doi/10.1046/j.1365-2958.2002.03173.x/abstract
40. Marcusson LL, Frimodt-Møller N, Hughes D (2009) Interplay in the selection of fluoroquinolone resistance and bacterial fitness. PLoS Pathog 5(8):e1000,541. doi:10.1371/journal.ppat. 1000541. http://dx.plos.org/10.1371/journal.ppat.1000541
41. Meredith HR, Srimani JK, Lee AJ, Lopatkin AJ, You L (2015) Collective antibiotic tolerance: mechanisms, dynamics and intervention. Nat Chem Biol 11(3):182–188. doi:10.1038/nchembio.1754. http://www.nature.com/nchembio/journal/v11/n3/full/nchembio.1754.html
42. Meulemans A (1992) A model of cefoperazone tissue penetration: diffusion coefficient and protein binding. Antimicrob Agents Chemother 36(2):295–298. http://aac.asm.org/content/36/2/295.short
43. Meulemans A, Paycha F, Hannoun P, Vulpillat M (1989) Measurement and clinical and pharmacokinetic implications of diffusion coefficients of antibiotics in tissues. Antimicrob Agents Chemother 33(8):1286–1290. http://aac.asm.org/content/33/8/1286.short
44. Moreno-Gamez S, Hill AL, Rosenbloom DI, Petrov DA, Nowak MA, Pennings P (2014) Imperfect drug penetration leads to spatial monotherapy and rapid evolution of multi-drug resistance. bioRxiv 013003. http://biorxiv.org/content/early/2014/12/19/013003.abstract
45. Mustoe T (2004) Understanding chronic wounds: a unifying hypothesis on their pathogenesis and implications for therapy. Am J Surg 187(5, Supplement 1), S65–S70. doi:10.1016/S0002-9610(03)00306-4. http://www.sciencedirect.com/science/article/pii/S0002961003003064
46. Nickel JC, Ruseska I, Wright JB, Costerton JW (1985) Tobramycin resistance of Pseudomonas aeruginosa cells growing as a biofilm on urinary catheter material. Antimicrob Agents Chemother 27(4):619–624. doi:10.1128/AAC.27.4.619. http://aac.asm.org/content/27/4/619
47. Nicolle LE, Strausbaugh LJ, Garibaldi RA (1996) Infections and antibiotic resistance in nursing homes. Clin Microbiol Rev 9(1):1–17. http://cmr.asm.org/content/9/1/1
48. Nowak MA (2006) Evolutionary dynamics. Harvard University Press
49. Oliver A, Cantón R, Campo P, Baquero F, Blázquez J (2000) High frequency of hypermutable pseudomonas aeruginosa in cystic fibrosis lung infection. science 288(5469):1251–1253. doi:10.1126/science.288.5469.1251. http://www.sciencemag.org/content/288/5469/1251
50. Organization WH, others (2001) WHO global strategy for containment of antimicrobial resistance. http://apps.who.int/iris/handle/10665/66860
51. Perron GG, Kryazhimskiy S, Rice DP, Buckling A (2012) Multidrug therapy and evolution of antibiotic resistance: when order matters. Appl Environ Microbiol 78(17):6137–6142. doi:10.1128/AEM.01078-12. http://aem.asm.org/content/78/17/6137
52. Poole K (2005) Aminoglycoside resistance in pseudomonas aeruginosa. Antimicrob Agents Chemother 49(2):479–487. doi:10.1128/AAC.49.2.479-487.2005. http://aac.asm.org/content/49/2/479
53. Regoes R, Wiuff C, Zappala R, Garner K, Baquero F, Levin B (2004) Pharmacodynamic functions: a multiparameter approach to the design of antibiotic treatment regimens. Antimicrob Agents Chemother 48(10):3670–3676
54. Rowland M, Tozer TN (1995) Clinical pharmacokinetics: concepts and applications
55. Schlegel HG, Zaborosch C, Kogut M (1993) General microbiology. Cambridge University Press
56. Singh PK, Schaefer AL, Parsek MR, Moninger TO, Welsh MJ, Greenberg EP (2000) Quorum-sensing signals indicate that cystic fibrosis lungs are infected with bacterial biofilms. Nature 407(6805):762–764. doi:10.1038/35037627. http://www.nature.com/nature/journal/v407/n6805/abs/407762a0.html
57. Smith SM, Eng RH, Tecson-Tumang F (1989) Ciprofloxacin therapy for methicillin-resistant Staphylococcus aureus infections or colonizations. Antimicrob Agents Chemother 33(2):181–184. doi:10.1128/AAC.33.2.181. http://aac.asm.org/content/33/2/181
58. Sniegowski PD, Gerrish PJ, Lenski RE (1997) Evolution of high mutation rates in experimental populations of E. coli. Nature 387(6634):703–705. doi:10.1038/42701. http://www.ncbi.nlm. nih.gov/pubmed/9192894
59. Stewart PS, William Costerton J (2001) Antibiotic resistance of bacteria in biofilms. The Lancet 358(9276):135–138. http://www.sciencedirect.com/science/article/pii/S0140673601053211
60. Toprak E, Veres A, Michel JB, Chait R, Hartl DL, Kishony R (2012) Evolutionary paths to antibiotic resistance under dynamically sustained drug selection. Nat Genet 44(1):101–105. doi:10.1038/ng.1034. http://dx.doi.org/10.1038/ng.1034
61. UK 5 year antimicrobial resistance strategy 2013–2018. https://www.gov.uk/government/publications/uk-5-year-antimicrobial-resistance-strategy-2013-to-2018
62. Vogne C, Aires JR, Bailly C, Hocquet D, Plésiat P (2004) Role of the multidrug efflux system Mexxy in the emergence of moderate resistance to aminoglycosides among Pseudomonas aeruginosa isolates from patients with cystic fibrosis. Antimicrob Agents Chemother 48 (5):1676–1680. doi:10.1128/AAC.48.5.1676-1680.2004. http://aac.asm.org/content/48/5/1676
63. Walsh F (2013) Antibiotics resistance ‘as big a risk as terrorism’—medical chief. http://www.bbc. co.uk/news/health-21737844
64. Westbrock-Wadman S, Sherman DR, Hickey MJ, Coulter SN, Zhu YQ, Warrener P, Nguyen LY, Shawar RM, Folger KR, Stover CK (1999) Characterization of a Pseudomonas aeruginosa efflux pump contributing to aminoglycoside impermeability. Antimicrob Agents Chemother 43 (12):2975–2983. http://aac.asm.org/content/43/12/2975
65. Yang L, Haagensen JAJ, Jelsbak L, Johansen HK, Sternberg C, Hoiby, N., Molin, S (2008) In situ growth rates and biofilm development of Pseudomonas aeruginosa populations in chronic lung infections. J Bacteriol 190(8):2767–2776. doi:10.1128/JB.01581-07. http://www.ncbi.nlm.nih. gov/pmc/articles/PMC2293235/
66. Zasloff M (2002) Antimicrobial peptides of multicellular organisms. Nature 415(6870):389–395. doi:10.1038/415389a. http://www.nature.com/nature/journal/v415/n6870/full/415389a.html
67. Zhang Q, Lambert G, Liao D, Kim H, Robin K, Tung CK, Pourmand N, Austin RH (2011) Acceleration of emergence of bacterial antibiotic resistance in connected microenvironments. Science 333(6050):1764–1767. doi:10.1126/science.1208747. http://www.sciencemag.org/cgi/doi/10.1126/science.1208747